stockrowInsulet Corporation
PODD Healthcare Medical Devices
Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024.
- Revenue
- +19.2%
- EPS
- +64.1%
- Free cash flow
- −29.8%
- Total debt
- −5.19%
Quarter to September 2026, against a year earlier
Follow PODD
Alert me
Insulet Corporation (PODD) Gross margin
Insulet Corporation's gross margin over the twelve months to 30 September 2026 was 71.9%, up 0.2 percentage points from fiscal 2025 (71.6%). Over the past ten years it has ranged from 50.5% (fiscal 2015) to 71.6% (fiscal 2025) — the current reading is the highest in ten years. That is above the Medical Devices industry median of 57.8% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 71.6% | 1.84 |
| FY2024 | 69.8% | 1.44 |
| FY2023 | 68.4% | 6.63 |
| FY2022 | 61.7% | (6.73) |
| FY2021 | 68.5% | 4.06 |
| FY2020 | 64.4% | (0.67) |
| FY2019 | 65.1% | (0.60) |
| FY2018 | 65.7% | 5.89 |
| FY2017 | 59.8% | 2.25 |
| FY2016 | 57.5% | 7.02 |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 75.1% | 4.89 |
| Jun 2026 | 70.2% | 0.73 |
| Mar 2026 | 69.5% | (3.09) |
| Dec 2025 | 72.5% | 0.32 |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| GKOS Glaukos Corporation compare | 81.1% |
| PODD Insulet Corporation | 71.9% |
| SNN Smith & Nephew SNATS, Inc. compare | 70.5% |
| TXG 10x Genomics compare | 70.0% |
| GMED Globus Medical, Inc. compare | 69.1% |
| PEN Penumbra, Inc. compare | 68.0% |
| BIO.B Bio-Rad Laboratories, Inc. compare | 51.3% |
| BIO Bio-Rad Laboratories, Inc. compare | 51.3% |
| BRKR Bruker Corporation compare | 47.7% |
| Medical Devices industry median | 57.8% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on PODD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement